Tuba Şaziye ÖZCAN, Yasemin KAYA, Erdal BENLİ, Fahriye Feriha ÖZER, Ali AYYILDIZ

Is there a difference between Parkinson disease patients and a control group in terms of urinary symptoms and quality of life?

Background/aim: The aim of this study is to research whether urinary symptoms and disruption of quality of life observed in Parkinson disease patients are different than those of their healthy peers. Additionally, whether these complaints were affected by characteristics such as age at onset of Parkinson disease, sex, disease duration, and severity was investigated. Materials and methods: This study comprised a total of 79 individuals, 39 Parkinson patients and a control group of 40 individuals. Parkinson diagnosis was provided by a neurology expert according to the UK Parkinson s Disease Society Brain Bank Criteria. All patients were evaluated by a urologist with the International Prostate Symptom Score (IPSS) and an overactive bladder (OAB) questionnaire. Results: Compared with the control group, the Parkinson patient group had statistically significantly higher rates of urological complaints (P < 0.001), irritative symptoms (P < 0.001), voiding symptoms (P < 0.001), OAB score (P < 0.001), IPSS total score (P = 0.007), and treatment requirements (P < 0.001). Conclusion: Urologic complaints were observed more frequently in the Parkinson patient group compared to the control group. Another important result of this study is that in the Parkinson patient group there was no difference found between urologic complaints in terms of sex.

PDF

___

1. Sakakibara R, Tateno F, Nagao T, Yamamoto T, Uchiyama T, Yamanishi T, Yano M, Kishi M, Tsuyusaki Y, Aiba Y. Bladder function of patients with Parkinsons disease. Int J Urol 2014; 21: 638-646.
2. Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinsons disease. J Neural Transm 2008; 115: 443-460.
3. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 2006; 25: 116-122.
4. Yoshimura N, Mizuta E, Kuno S, Sasa M, Yoshida O. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 1993; 32: 315-321.
5. Winge K, Nielsen KK. Bladder dysfunction in advanced Parkinsons disease. Neurourol Urodyn 2012; 31: 1279-1283.
6. Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinsons disease patients with the wearing-off phenomenon. Mov Disord 2003; 18: 573-578.
7. Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinsons disease. Neurobiol Dis 2012; 46: 565-571.
8. Fahn S, Elton RL. Unified Parkinsons Disease Rating Scale. In: Fahn S, Marsden CD, Goldsteijn M, Calne DB, editors. Recent Developments in Parkinsons Disease. Florham Park, NJ, USA: Macmillan Healthcare Information; 1987. pp. 153-163.
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
10. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185: 1793-1803.
11. Chapple CR, Roehrborn CG, McVary K, Ilo D, Henneges C, Viktrup L. Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials. Eur Urol 2015; 67: 114-122.
12. Galloway NT. Urethral sphincter abnormalities in Parkinsonism. Br J Urol 1983; 55: 691-693.
13. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International. Continence Society. Am J Obstet Gynecol 2002; 187: 116-126.
14. Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM Jr, Ribeiro SC, de Carvalho DF. Urinary symptoms in Parkinsons disease: prevalence and associated factors. Arq Neuropsiquiatr 2003; 61: 359-363.
15. Lemack GE, Dewey RB Jr, Roehrborn CG, OSuilleabhain PE, Zimmern PE. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinsons disease. Urology 2000; 56: 250-254.
16. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinsons disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000; 68: 429-433.
17. Reggio E, de Bessa J Jr, Junqueira RG, Timm O Jr, Sette MJ, Sansana V, Gomes CM. Correlation between lower urinary tract symptoms and erectile dysfunction in men presenting for prostate cancer screening. Int J Impot Res 2007; 19: 492-495.
18. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinsons disease. J Urol 1983; 129: 80-83.
19. Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, Hattori T. Questionnaire-based assessment of pelvic organ dysfunction in Parkinsons disease. Auton Neurosci 2001; 92: 76-85.
20. Myers DL, Arya LA, Friedman JH. Is urinary incontinence different in women with Parkinsons disease? Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 188-191.
21. Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinsons disease: urodynamic abnormalities and urinary symptoms. J Urol 2000; 164: 1640-1643.
22. Sammour ZM, Gomes CM, Barbosa ER, Lopes RI, Sallem FS, Trigo-Rocha FE, Bruschini H, Srougi M. Voiding dysfunction in patients with Parkinsons disease: impact of neurological impairment and clinical parameters. Neurourol Urodyn 2009; 28: 510-515.
23. Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinsons disease: changes relate to age and not disease. Age Ageing 1995; 24: 499-504.
24. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinsons disease. Neurology 1989; 39: 1187- 1190.
25. Ozcan T, Benli E, Demir EY, Ozer F, Kaya Y, Haytan CE. The relation of sexual dysfunction to depression and anxiety in patients with Parkinsons disease. Acta Neuropsychiatr 2015; 27: 33-37.
26. Benli E, Keleş İ, Ceylan C, Geçit İ, Ateş C. The level of the understandability of the IPSS form by the patients in different regions of Turkey. Turkiye Klinikleri J Urology 2012; 3: 36-40 (in Turkish with English abstract).
27. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 2006; 2: 116-122.
28. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49.
29. Iacovelli E, Gilio F, Meco G, Fattapposta F, Vanacore N, Brusa L, Giacomelli E, Gabriele M, Rubino A, Locuratolo N et al. Bladder symptoms assessed with overactive bladder questionnaire in Parkinsons disease. Mov Disord 2010; 25: 1203-1209.
30. Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinsons disease. Eur J Neurol 2005; 12: 842-850.